pembrolizumab as second-line therapy for advanced urothelial carcinoma
Published 7 years ago • 9.3K plays • Length 2:05Download video MP4
Download video MP3
Similar videos
-
2:22
pembrolizumab as second-line therapy for advanced urothelial carcinoma
-
2:12
neoadjuvant pembrolizumab for lung cancer | nejm
-
1:09
keynote-045 – pembrolizumab as second-line treatment in urothelial carcinoma
-
1:45
results for pembrolizumab as a first-line therapy for advanced urothelial carcinoma
-
4:34
optimising treatment for advanced urothelial cancer: combination, maintenance or sequencing?
-
1:04
choosing second-line therapy for patients with urothelial carcinoma
-
6:01
enfortumab vedotin plus pembrolizumab improves overall survival for advanced bladder cancer
-
19:21
immunotherapy for muscle invasive bladder cancer
-
15:53
ev-103 study by dr. jonathan rosenberg led to the fda approval of enfortumab pembrolizumab
-
1:58
results for first-line pembrolizumab in advanced urothelial carcinoma
-
1:00
adjuvant pembrolizumab for bladder cancer
-
0:35
ev-302: 1l enfortumab vedotin in combination with pembrolizumab
-
1:48
what does the 2-year follow-up tell us about the use of pembrolizumab for advanced bladder cancer?
-
1:04
treatment considerations for patients with metastatic urothelial carcinoma
-
1:10
fda grants accelerated approval to enfortumab vedotin-ejfv with pembrolizumab for bladder cancer
-
0:09
urothelial carcinoma
-
1:37:40
integrating care for oncology patients: establishing a multidisciplinary oncology clinic
-
0:16
imvigor 210 results in metastatic urothelial carcinoma
-
1:09
dr. plimack on frontline pembrolizumab for urothelial carcinoma